Daily Archives: December 1, 2016


 Protocol Summary:  This is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding maraviroc (MVC) and dolutegravir (DTG) to the current antiretroviral therapy (ART) of HIV-infected individuals who have at least mild neurocognitive impairment with a primary outcome of improvement in neurocognitive performance. Purpose of This […]

A5324: To see if adding extra anti-HIV medicines reduces HIV-associated ...


Protocol Summary and Purpose of this Study:   This is a randomized, open-label, two-arm (phase IIa) study of ruxolitinib in HIV-infected adults. Eligible participants on select antiretroviral therapy (ART) with virologic suppression will be randomized to receive ruxolitinib or no study treatment to measure safety, tolerability, PK and to determine whether […]

A5336: A Study of Ruxolitinib in ART-Treated HIV-1 Infected Adults